CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.)

365 articles about CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.)

• CASI Pharmaceuticals Announces Third Quarter 2023 Business and Financial Updates

  11/14/2023

  CASI Pharmaceuticals, Inc. reported business and financial results for the third quarter ended September 30, 2023.

• CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

  11/8/2023

  CASI Pharmaceuticals Inc. is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas).

• CASI Pharmaceuticals Announces Second Quarter 2023 Business and Financial Updates

  8/11/2023

  CASI Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported financial results for the quarter ended June 30, 2023.

• Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

  8/1/2023

  CASI Pharmaceuticals, Inc. announced the execution of an Assignment Agreement with Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. for the commercialization of FOLOTYN® in the People's Republic of China.

• Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

  7/20/2023

  Cleave Therapeutics, Inc. today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.

• CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

  7/20/2023

  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product.

• CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

  5/17/2023

  CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2023.

• CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

  4/26/2023

  CASI Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission on April 26, 2023.

• CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

  4/26/2023

  CASI Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022. 

• Casi Pharmaceuticals Completes Redomiciliation Merger

  3/21/2023

  CASI Pharmaceuticals, Inc. announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company has been completed.

• CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

  1/6/2023

  CASI Pharmaceuticals, Inc. announces that the China National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics.

• CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  12/15/2022

  CASI Pharmaceuticals, Inc. today announces that China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) from Juventas Cell Therapy, Ltd., (Juventas) for CNCT19 (Inaticabtagene Autoleucel).

• CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

  11/14/2022

  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2022.

• CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

  9/23/2022

  CASI Pharmaceuticals, Inc. today announced that CASI Biopharmaceuticals (Wuxi) Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. ("CASI Wuxi"), entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP ("Jiadao Gongcheng"), pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology (Tianjin) Co., Ltd.

• CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

  8/12/2022

  CASI Pharmaceuticals, Inc. today reported financial results for the second quarter of 2022.

• CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

  8/5/2022

  CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. EST on Friday, August 12, 2022.

• CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

  7/8/2022

  Precision Autoimmune Therapeutics (PAT) Announced the completion of first-round financing of the equivalent of approximately US $21 million.

• Casi Pharmaceuticals Announces Reverse Stock Split - May 26, 2022

  5/26/2022

  CASI Pharmaceuticals, Inc. announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-10 reverse stock split that will become effective at 5:00 p.m., Eastern Time, on June 1, 2022.

• CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD

  5/24/2022

  CASI Pharmaceuticals, Inc. today announced the signing of a Sublicense Agreement with Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd., ("TIANSHI") a clinical stage pharmaceutical company organized and existing under the laws of the People's Republic of China ("PRC").

• CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

  5/12/2022

  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2022.